COMT

Catechol-O-methyltransferase

COMT

Related Products

Catechol O-methyltransferase (COMT) is the enzyme responsible for the O-methylation of endogenous neurotransmitters and of xenobiotic substances and hormones incorporating catecholic structures. COMT is present in mammals as soluble (S-COMT) and membrane-bound (MB-COMT) forms. S-COMT is the predominant form of COMT in the peripheral organs and MB-COMT is more abundant in the Central Nervous System.

Physiological substrates of COMT include L-dopa, catecholamines (dopamine, norepinephrine, and epinephrine), their hydroxylated metabolites, catecholestrogens, ascorbic acid, and dihydroxyindolic intermediates of melanin. Specifically, COMT plays a critical role in the inactivation and metabolism of dopamine and other catechol compounds. The enzyme reduces a catechol molecule in order to prevent genomic damage through DNA adduct formation or via oxygen radicals produced from the redox cycling of catechols. COMT is a druggable biological target for the treatment of various central and peripheral nervous system disorders, including Parkinson's disease, depression, schizophrenia, and other dopamine deficiency-related diseases.

COMT Inhibitors (29)

COMT Related Products (31):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-17406S

Tolcapone-d₇	Inhibitor
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-17406R

Tolcapone (Standard)	Inhibitor
Tolcapone (Standard) is the analytical standard of Tolcapone. This product is intended for research and analytical applications. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC₅₀ of 773 nM in the liver. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma.

HY-151390

hMAO-B/MB-COMT-IN-2	Inhibitor
hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-100642S1

3-O-Methyltolcapone-d₄	Inhibitor
3-O-Methyltolcapone-d₄ is the deuterium labeled 3-O-Methyltolcapone. 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone. Tolcapone is an orally active, reversible, selective and potent COMT inhibitor. Tolcapone crosses the blood-brain barrier, and can be used for treatment of Parkinson's disease[1][2].

HY-162760

COMT-IN-1	Inhibitor
COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC₅₀s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice.

HY-N0529R

Rosmarinic acid (Standard)	Inhibitor
Rosmarinic acid (Standard) is the analytical standard of Rosmarinic acid. This product is intended for research and analytical applications. Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits MAO-A, MAO-B and COMT enzymes with IC₅₀s of 50.1, 184.6 and 26.7 μM, respectively.

HY-168154

COMT-IN-2	Inhibitor
COMT-IN-2 (compund 9) is the potent COMT inhibitor, showing selective inhibition of brain (IC₅₀=24 nM) and liver (IC₅₀=81 nM) MB-COMT compared to the liver S-COMT (IC₅₀=620 nM) isoform.

HY-14896R

Opicapone (Standard)	Inhibitor
Opicapone (Standard) is the analytical standard of Opicapone. This product is intended for research and analytical applications. Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC₅₀ of 98 μM.

HY-14280A

Entacapone sodium salt	Inhibitor
Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease. Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders.

HY-100642R

3-O-Methyltolcapone (Standard)	Inhibitor
3-O-Methyltolcapone (Standard) is the analytical standard of 3-O-Methyltolcapone. This product is intended for research and analytical applications. 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone. Tolcapone is an orally active, reversible, selective and potent COMT inhibitor. Tolcapone crosses the blood-brain barrier, and can be used for treatment of Parkinson's disease.

HY-119224

BIA 3-335	Inhibitor
BIA 3-335 is an inhibitor for catechol-O-methyltransferase (COMT), and can be used in research about Parkinson's disease.

Name
Email *

	Sorry, but the email address you supplied was invalid.